Company intelligence / Profile preview

SBI

Tokyo, Tokyo, Japan

Ownership: Private
Employees: ~22
Development stage: Other

Overview

SBI Biotech focuses on dendritic cell-targeted drugs for cancer and autoimmune diseases, licensing out early-stage assets. Their anti-ILT7 antibody (VIB 7734) entered Phase I trials in 2016 (under MedImmune/Viela Bio), and SBI－9674 (licensed to Kyowa Kirin) is approaching clinical trials. SBI－3150 (licensed to Asahi Kasei Pharma) is at the preclinical stage. Programs are out-licensed to partners for later-stage development

Therapeutic areas: OncologyRare DiseasesImmunology
Modalities: Monoclonal antibodySmall moleculeNucleic acid drugsCell therapyProtein/antibody drugsNutraceuticals
Industry: Biotech

Partnerships

Kyowa KirinViela Bio (acquired by Horizon; program originated with MedImmune)Asahi Kasei PharmaHelixir (Korean biotech; PG102 nutraceutical)

Beyond the preview

Go deeper on SBI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBI.

Explore the full profile